Association between Traditional Chinese Medicine Use and Liver Cancer in Patients with Liver Cirrhosis: A Population-based Study

Similar documents
Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants

Incidence and Risk of Alcohol Use Disorders by Age, Gender and Poverty Status: A Population-Based-10 Year Follow-Up Study

2015 Annual Report Taiwan Blood Services Foundation

Malignant transformation of oral submucous fibrosis in Taiwan: A nationwide population-based retrospective cohort study

A Nation-wide Investigation of Real-World Community Effectiveness in HCV Treatment for Policy-making Toward Elimination of HCV by 2030 in Taiwan

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Changing epidemiology of HCC in Italy

Viral hepatitis and Hepatocellular Carcinoma

Life After SVR for Cirrhotic HCV

Natural History of HBV Infection

Physician specialty and the outcomes and cost of admissions for end-stage liver disease Ko C W, Kelley K, Meyer K E

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

VOICES OF THE HIDDEN

Hepatitis B virus (HBV) infection is a global

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals

Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview.

Does Viral Cure Prevent HCC Development

Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B

Supplementary Information. Statins Improve Long Term Patency of Arteriovenous Fistula for

Healthy Liver Cirrhosis

Ammonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis

King Abdul-Aziz University Hospital (KAUH) is a tertiary

Complications Requiring Hospital Admission and Causes of In-Hospital Death over Time in Alcoholic and Nonalcoholic Cirrhosis Patients

HCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

Effect of Ultrasonography Surveillance on Survival of Patients with Liver Cancer: a Population-Based Longitudinal Study For peer review only

Tel: , Tel: ext 8326, Fax: ,

Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation

ORIGINAL INVESTIGATION. Smoking and Alanine Aminotransferase Levels in Hepatitis C Virus Infection

Changes in Serum Levels of HBV DNA and Alanine Aminotransferase Determine Risk for Hepatocellular Carcinoma

Hepatology For The Nonhepatologist

Association between obesity, hypertriglyceridemia and low hepatitis B viral load

Clinical Trials & Endpoints in NASH Cirrhosis

Hepatitis B virus (HBV) infection is an important. Brief Communication

Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018

COST-EFFECTIVENESS ANALYSIS OF ORAL CAVITY CANCER IN TAIWAN: A POPULATION-BASED STUDY

Risk of pneumonia among patients with splenectomy: a retrospective populationbased

The Epidemiologic Transition of Diabetes Mellitus in Taiwan: Implications for Reversal of Female Preponderance from a National Cohort

The effect of bacterial infections in cirrhotic patients with esophageal variceal bleeding

Taipei 10070, Taiwan (R.O.C) Taipei Date submitted to OIE 17/03/2017

Liver Transplantation: The End of the Road in Chronic Hepatitis C Infection

Journal of Antimicrobial Chemotherapy Advance Access published April 25, 2013

Liver transplant: what is left after the viruses

Accepted Manuscript. Chun-Ying Wu, Jaw-Town Lin, Hsiu J. Ho, Chien-Wei Su, Teng-Yu Lee, Shen-Yung Wang, Chuhui Wu, Jaw-Ching Wu

During the past 2 decades, an increase in the ageadjusted

Need for long-term evaluation of therapy in Chronic Hepatitis B

PREVALENCE OF NAFLD & NASH

Cigarette Smoking And Hepatocellular Carcinoma Risk In Xiamen, China

Chronic hepatitis B virus (HBV) infection remains a major

HEPATOCELLULAR CARCINOMA: AN OVERVIEW

The Impact of Chronic Liver Disease on Postoperative Outcomes and Resource Utilization within the National Surgical Quality Improvement Database

Liver resection for HCC

The Impact of HBV Therapy on Fibrosis and Cirrhosis

Learning Objectives. After attending this presentation, participants will be able to:

Predictors of Cigarette Smoking Behavior Among Military University Students in Taiwan. Wang, Kwua-Yun; Yang, Chia-Chen

The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an open-label, randomized controlled trial

IL10 rs polymorphism is associated with liver cirrhosis and chronic hepatitis B

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

RESEARCH ARTICLE. Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment

NIH Public Access Author Manuscript J Surg Res. Author manuscript; available in PMC 2011 May 18.

Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation

Herpes zoster, or shingles, is caused by

Demographic Factors Influencing Hepatitis B infection towards Bad Prognosis in a Sample of Iraqi Patients

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

The Diabetes Epidemic in Korea

Is exposure to Agent Orange a risk factor for hepatocellular cancer? A single-center retrospective study in the U.S. veteran population

Standing Posture at Work Does Not Increase the Risk of Varicose Veins among Health Care Providers in Taiwan

Management of HepatoCellular Carcinoma

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

FORECASTING DEMAND OF INFLUENZA VACCINES AND TRANSPORTATION ANALYSIS.

Age-Period-Cohort Analysis of Hepatocellular Carcinoma Mortality in Taiwan,

The place of bariatric surgery in NASH: can we extend the indications? - No

HCC: Is it an oncological disease? - No

Surveillance for Hepatocellular Carcinoma

JMSCR Vol 05 Issue 11 Page November 2017

J.Y. WANG 1, A.C. TSAI 1,2

HBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

Liver Pathology in the 0bese

Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

Worldwide Causes of HCC

Detection of Esophageal Varices in Liver Cirrhosis Using Non-invasive Parameters

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING

T he polyvinyl chloride (PVC) polymerisation process has

Hepatocellular Carcinoma (HCC): Burden of Disease

GR-MD-02 for Indication of NASH Cirrhosis: NASH-CX Clinical Trial Results

Chronic infection with hepatitis B virus (HBV) is still a

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

Hepatocellular Carcinoma. Markus Heim Basel

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:

/Webpages/zhang/chinese-full full- program.htm

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Carvedilol or Propranolol in the Management of Portal Hypertension?

CURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

European. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes

Liver Cancer Screening in Korea: A Report on the 2008 National Cancer Screening Programme

Socioeconomic status risk factors for cardiovascular diseases by sex in Korean adults

White Nights of Hepatology 2016

Clinical Staging for Hepatocellular Carcinoma: Eastern Perspectives. Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan

Staging and prognostic systems: beyond BCLC?

Transcription:

Research Article imedpub Journals http://www.imedpub.com/ Journal of Cancer Epidemiology and Prevention Association between Traditional Chinese Medicine Use and Liver Cancer in Patients with Liver Cirrhosis: A Population-based Study Chen YL 1, Lung CC 1,2, Huang JY 1, Nfor ON 1, Ko PC 1 and Liaw YP 1,2* 1 School of Public Health, Chung Shan Medical University, Tai-Chung, Taiwan 2 Department of Family and Community Medicine, Chung Shan Medical University Hospital, Tai-Chung, Taiwan Corresponding author: Liaw YP, Department of Public Health and Institute of Public Health, Chung Shan Medical University, No. 110, Section 1 Jianguo N. Road, Taichung City 40201, Taiwan, Tel: +886-4-24730022 ext. 11838; Fax: +886-4-23248179; E-mail: Liawyp@csmu.edu.tw Received date: February 22, ; Accepted date: March 10, ; Published date: April 01, Citation: Liaw YP, Chen YL, Lung CC, et al. Association between Traditional Chinese Medicine Use and Liver Cancer in Patients with Liver Cirrhosis: A Population-based Study. J Cancer Epidemiol Prev., 2:1. Abstract Background The global incidence and mortality of liver diseases is increasing. One of the major risk factors for liver cancer is the presence of liver cirrhosis. Traditional Chinese medicines (TCM) are being sought as alternative medicines for liver diseases. This study evaluated the association between traditional Chinese herbal medicine and liver cancer in patients with liver cirrhosis. Methods The analytical data were collected from the Longitudinal Health Insurance Databases (LHID2005). Samples included patients with liver cirrhosis who sought Traditional Chinese medicine from 2001-2004. Diagnosis of liver cancer was from 2004-2010 using the ICD 9 codes 155 and A code A095. The Chi-square (χ2) test was used to test for associations while multivariate logistic regression was used to investigate the association between CM and liver cancer in cirrhotic patients. All statistics were analyzed using the SAS 9.2 software (Cary, NC, USA). Differences were considered significant at p-value< 0.05. Results From 2001-2004, a total of 8 145 individuals were identified with liver cirrhosis; 5 469 were men and 2 676 were women. Among the cirrhotic patients who sought TCM, 25.3% of men and 20.41% of women were identified with liver cancer. Multivariate logistic regression analysis showed a significant odds ratio (OR) of 0.880 (95% CI 0.787-0.984) for liver cancer. However, when analyzed by gender, significant odds existed only in men (OR: 0.872, 95% CI 0.764-0.955). Conclusion There was a significant association between traditional Chinese medicine and liver cancer in men with cirrhosis. Keywords: Cirrhosis; Liver cancer; Chinese herbal medicine Introduction Hepatocellular carcinoma (HCC) is the seventh most frequent cancer and the third leading cause of cancer-related death worldwide [1]. Cirrhosis is the strongest predisposing factor for HCC. Approximately 80% of cases with HCC develop in cirrhotic liver [2]. The annual incidence of HCC in patients with and without cirrhosis is 2.0-6.6 and 0.4%, respectively [2]. Variceal bleeding is one of the commonest and most severe complications of liver cirrhosis. When cirrhosis is diagnosed, varices are present in about 30-40% of compensated patients and in 60% of those who present with ascites [3]. There is no effective medication to prevent the development of varices [4]. Liver transplantation (LT) may serve as the best treatment choice for varices [5,6]. However, shortage of donor organs is a serious well known limitation [7]. Because of the complexity and difficulty involved in the treatment of liver cirrhosis, many patients seek traditional Chinese Herbal medicine (an alternative treatment). A previous study has reported the therapeutic and beneficial effects of Chinese medicine on hepatic fibrosis [8]. Chinese Medicine has also been linked to hepatoprotective effect in cirrhotic patients [9]. However, studies to investigate the links between TCM and liver cancer among patients with liver cirrhosis using a large-scale database are limited. Therefore, this study was conducted to assess the relationship between traditional Chinese herbal medicine and liver cancer in patients with liver cirrhosis. Copyright imedpub This article is available from: http://www.imedpub.com/cancer-epidemiology-and-prevention/ 1

Methods The study data were collected from the National Health Insurance Research Database (NHIRD) which contains detailed clinical records of every patient on each visit. It also includes primary and secondary diagnostic codes as well as prescription orders. A randomized sample of 1,000,000 individuals were retrieved from the LHID2005. The database contained deidentified data hence, ethics approval was not required. Cirrhotic patients were either identified from the CD (ambulatory care expenditures by visit) or DD (inpatient expenditures by admission) datasets using the codes 571.2, 571.5, 571.6 and A code A347. The study samples included a total of 8145 cirrhotic patients: 4,509 who sought and 3,636 who did not seek TCM from 2001-2004). Excluded were individuals who were diagnosed with liver cancer from 2001 to 2004 and those who sought TCM during 2005-2010. Liver cancer diagnosis was from 2004-2010 using the ICD 9 code 155 and Acode A095. Information about the demographic variables, insurance cost and geographical region is contained in the NHIRD. Household income was categorized into four groups: family dependent, $20,000, $20,000 to less than $40,000, and $40,000. Insurance has been categorized into mainly six regions according to geographic and administrative districts: Taipei (Taipei City, Taipei County, Keelung City, Yilan County, Kinmen County, Lianjiang County), Northern (Taoyuan County, Hsinchu City, Hsinchu County, Miaoli County), Central (Taichung City, Taichung County, Changhua County, Nantou County), Southern (Tainan City, Tainan County, Chiayi City, Chiayi County, Yunlin County), Kao-Ping (Kaohsiung City, Kaohsiung County, Pingtung County, Penghu County), and Eastern region (Hualien County, Taitung County). Adjustments were made for socio-demographic characteristics (Table 1) as well as other potential confounders (hepatitis B virus, hepatitis C virus, chronic hepatitis, alcoholic hepatitis). Table 1 Demographic characteristics of patients who sought TCM (age 30), age was mean ± S.E. TCM from 2001-2004 No TCM from 2001-2004 (n=4 509) (n=3 636) Number % Number % P -value Age (2005) 55.62 ± 15.47 56.53 ± 16.11 0.0095 Sex <0.0001 Men 2 749 60.97 2 720 74.81 Women 1 760 39.03 916 25.19 Household income <0.0001 Dependent 1 107 24.55 800 22.00 <20 000 2 303 51.08 2 107 57.95 20 000-39 999 691 15.32 449 12.35 40 000 408 9.05 280 7.70 Geographic area <0.0001 Taipei City 1 284 28.48 965 26.54 North 544 12.06 504 13.86 Central 932 20.67 527 14.49 South 775 17.19 753 20.71 Kaohsiung-Pingtung 785 17.41 696 19.14 East 189 4.19 191 5.25 Liver cancer 0.0267 Yes 1 042 23.11 917 25.55 No 3 467 76.89 2 719 74.78 Chronic hepatitis <0.0001 2 This article is available from: http://www.imedpub.com/cancer-epidemiology-and-prevention/

Yes 2 864 63.52 1 973 54.26 No 1 645 36.48 1 663 45.74 Hepatitis B 0.0012 Yes 1 116 24.75 789 21.70 No 3 393 75.25 2 847 78.30 Hepatitis C <0.0001 Yes 954 21.16 624 17.16 No 3 555 78.84 3 012 82.84 Alcoholic hepatitis 0.9446 Yes 286 6.34 232 6.38 No 4 223 93.66 3 404 93.62 Statistical analysis The study participants were categorized into 18, 18-40, and 40 age groups. T-test was used to analyze the age differences between individuals who received TCM and those who did not. Chi square test was used to assess the links between TCM and categorical variables while multivariate logistic regression was used to evaluate the relationship between TCM and liver cancer. All analyses were made using the SAS software (version 9.2, Cary, NC, USA). Differences were considered significant at p-value<0.05. Results A total of 8,145 cirrhotic individuals aged 30 years and older were enrolled in this study. The mean age of cirrhotic men who sought TCM treatment was significantly less than that of those who never sought any treatment (p<0.0001) as shown in Table 2. About 25.03% of cirrhotic men who sought TCM and 26.78% of those who never sought TCM were diagnosed with liver cancer. As shown in Table 3, the mean age of cirrhotic women who sought TCM treatment was significantly lower than that of those who did not (p<0.0001). About 20.11% of cirrhotic men who sought TCM and 20.41% of those who never sought TCM were diagnosed with liver cancer. Results of multivariate logistic regression models stratified by gender and adjusted for insurance cost, geographical region and related confounders (hepatitis B virus, hepatitis C virus, chronic hepatitis, alcoholic hepatitis) are shown in Table 4. In the first model, the odds ratio of developing liver cancer in cirrhotic patients who sought TCM was (OR 0.880, 95% CI 0.787-0.984). Further analysis showed significant odds ratio only in men (0.872, 95% CI 0.764-0.955). Table 2 Demographic characteristics of cirrhotic men who sought TCM (age 30), age was mean ± S.E. TCM from 2001-2004 No TCM from 2001-2004 (n=2 749) (n=2 720) Number % Number % P-value Age (2005) 52.61 ± 15.06 54.55 ± 15.54 <0.0001 Household income Dependent 473 17.21 452 16.62 <0.0001 <20,000 1 477 53.73 1 656 60.88 20,000-39,999 450 16.37 368 13.53 40,000 349 12.70 244 8.97 Geographic area <0.0001 Taipei City 789 28.70 715 26.29 North 333 12.11 395 14.52 Central 570 20.73 416 15.29 Copyright imedpub 3

South 428 15.57 533 19.60 Kaohsiung-Pingtung 505 18.37 525 19.30 East 124 4.51 136 5.00 Liver cancer 0.1265 Yes 688 25.03 730 26.84 No 2 061 74.97 1 990 73.16 Chronic hepatitis <0.0001 Yes 1 745 63.48 1 469 54.01 No 1 004 36.52 1 251 45.99 Hepatitis B 0.0069 Yes 736 26.77 642 23.60 No 2 013 73.23 2 078 76.40 Hepatitis C 0.0694 Yes 467 16.99 413 15.18 No 2 282 83.01 2 307 84.82 Alcoholic hepatitis 0.1311 Yes 255 9.28 221 8.13 No 2 494 90.72 2 499 91.88 Table 3 Demographic characteristics of cirrhotic women who sought TCM (age>30), age was mean ± S.E. TCM from 2001-2004 No TCM from 2001-2004 (n=1760) (n=916) Number % Number % P-value Age (2005) 60.30 ± 14.93 62.42 ± 16.32 0.0011 Household income 0.0034 Dependent 634 36.02 348 37.99 <20 000 826 46.93 451 49.24 20,000-39,999 241 13.69 81 8.84 40 000 59 3.35 36 3.93 Geographic area <0.0001 Taipei City 495 28.13 250 27.29 North 211 11.99 109 11.90 Central 362 20.57 111 12.12 South 347 19.75 220 24.02 Kaohsiung-Pingtung 280 15.91 171 18.67 East 65 3.69 55 6.00 Liver cancer 0.8539 Yes 354 20.11 187 20.41 4 This article is available from: http://www.imedpub.com/cancer-epidemiology-and-prevention/

No 1 406 79.89 729 79.59 Chronic hepatitis <0.0001 Yes 1.119 63.58 504 55.02 No 641 36.42 412 44.98 Hepatitis B 0.0006 Yes 380 21.59 147 16.05 No 1.380 78.41 769 83.95 Hepatitis C 0.0096 Yes 487 27.67 211 23.03 No 1.273 72.33 705 76.97 Alcoholic hepatitis 0.2684 Yes 31 1.76 11 1.20 No 1.729 98.24 905 98.80 Table 4 Risk of liver cancer in cirrhotic patients who sought TCM, adjusted for age, sex, household income and region. Total Men Women O.R 95% C.I O.R 95% C.I O.R 95% C.I TCM in 2001-2004 Yes 0.880 0.787-0.984 0.872 0.764-0.955 0.893 0.722-1.104 No 1.000-1.000-1.000 - Age (2005) 1.027 1.022-1.031 1.028 1.023-1.033 1.022 1.013-1.031 Sex Male 1.000 - Female 1.937 1.705-2.200 Household income Dependent 1.189 1.035-1.366 1.355 1.132-1.622 0.936 0.751-1.167 <20 000 1.000-1.000-1.000-20,000-39,999 1.184 0.999-1.403 1.308 1.077-1.589 0.839 0.585-1.203 40 000 1.089 0.884-1.343 1.187 0.949-1.484 0.607 0.301-1.222 Geographic area Taipei City 1.000-1.000-1.000 - North 0.890 0.740-1.070 0.960 0.772-1.194 0.719 0.506-1.022 Central 0.903 0.764-1.068 0.918 0.750-1.124 0.880 0.653-1.186 South 0.940 0.797-1.108 1.055 0.863-1.289 0.718 0.535-0.962 Kaohsiung-Pingtung 1.004 0.852-1.183 1.150 0.947-1.396 0.710 0.519-0.970 East 0.549 0.398-0.757 0.540 0.366-0.795 0.588 0.332-1.041 Co-morbidity Chronic hepatitis 1.173 1.041-1.322 1.085 0.942-1.250 1.417 1.131-1.776 Copyright imedpub 5

Hepatitis B 2.696 2.386-3.046 3.111 2.692-3.595 1.802 1.424-2.282 Hepatitis C 2.491 2.186-2.839 2.384 2.018-2.817 2.642 2.138-3.265 Alcoholic hepatitis 0.431 0.317-0.585 0.475 0.348-0.649 <0.001 - Discussion To our knowledge, this is the first nationwide populationbased study to evaluate the relationship between liver cirrhosis, Chinese traditional medicine and liver cancer. Cirrhotic men who received TCM had a significantly lower risk of liver cancer. The risk was also lower but insignificant in their female counterparts. There may have been an interaction effect of TCM and hormones on liver cirrhosis. Future studies would help to clarify such interactions. In Taiwan, liver cancer accounts for more than 28% of total deaths [10]. The annual standardized mortality incidence increased from 22.7/100 000 in 1991 to 26.2/100 000 in 2009 [10]. The majority of patients with hepatocellular carcinoma (HCC) worldwide have underlying cirrhosis [11]. Hepatocellular carcinoma occurs at a rate of 1 to 4% per year after cirrhosis is established [12] while cirrhosis underlies HCC in approximately 80%-90% of cases worldwide [13]. Preventing the development of liver cancer in patients with liver cirrhosis is an important public health issue. In Taiwan, chronic hepatitis B and C are the leading causes of liver cirrhosis [14-16]. About 95% of liver cirrhosis is caused by both B and C types of hepatitis viruses. Other causes include alcohol, chronic hepatitis, and persistence [14]. In this study, adjustments were made for potential confounders such as hepatitis B, C, alcohol and chronic hepatitis. HCC was significantly lower in cirrhotic patients who had received TCM. The mean age of cirrhotic men who were exposed to TCM was below that of their non-exposed counterparts. Significant association between traditional Chinese medicine and liver cancer was found only in men. More studies that take into account gender disparity are essential. This study has some limitations. First, no specific Chinese medicine was included in the model. Second, there is a dearth of information about the stage of liver cirrhosis. Third, the NHIRD contain records of different scientifically processed Chinese herbal medications whose herbal preparations range from a single to multi-ingredient preparations. This makes it difficult to determine how frequently the patients were taking the medications. Finally, adjustments were not made for potential behavioral confounders such as smoking and drinking. Conclusion There was a significant association between traditional Chinese medicine and liver cancer in men with cirrhosis. Conflict of Interest Authors have no conflict of interest to disclose. Acknowledgments Authors express sincere thanks to Chung Shan Medical University and the entire team that assisted in realizing this work. References 1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, et al. (2008) Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10, Lyon, GLOBOCAN, France. IARC, p: 2. 2. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362: 31907-31917. 3. D Amico G (2004) Esophageal varices: from appearance to rupture; natural history and prognostic indicators, Portal hypertension in the 21st century, pp: 147-154. 4. Garcia-Tsao G (2007) Preventing the development of varices in cirrhosis. J clinic gastro 41: 300-304. 5. Iwatsuki S, Starzl TE, Todo S, Gordon RD, Tzakis AG, et al. (1988) Liver transplantation in the treatment of bleeding esophageal varices. Surg 104:697. 6. Reyes J, Iwatsuki S (1991) Current management of portal hypertension with liver transplantation. Adv surg 25: 189-208. 7. Orloff MJ, Isenberg JI, Wheeler HO, Haynes KS, Brook JH, et al. (2010) Liver transplantation in a randomized controlled trial of emergency treatment of acutely bleeding esophageal varices in cirrhosis. Trans proc, pp: 4101-4108. 8. Wang P, Liang YZ (2010) Chemical composition and inhibitory effect on hepatic fibrosis of Danggui Buxue Decoction. Phytothe 81: 793-798. 9. Huseini HF, Alavian S, Heshmat R, Heydari M, Abolmaali K (2005) The efficacy of Liv-52 on liver cirrhotic patients: a randomized, double-blind, placebo-controlled first approach. Phytomed 12: 619-624. 10. Health Do Standardized cancer mortality from Department of Health, R.O.C. Department of Health, Taiwan. 11. Simonetti RG, Camma C, Fiorello F, Politi F, D'Amico G, et al. (1991) Hepatocellular carcinoma- A worldwide problem and the major risk factors. Digest dis and sci 36: 962-972. 12. Bisceglie AM (1997) Hepatitis C and hepatocellular carcinoma. Hepatology 26: 34-38. 13. Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterol 127: 35-50. 14. Liaw YF, Tai DI, Chu CM, Chen TJ (1988) The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatol 8: 493-496. 15. Kao JH, Tsai SL, Chen PJ, Yang PM, Sheu JC, et al. (1994) A clinicopathologic study of chronic non-a, non-b (type C) hepatitis in Taiwan: comparison between posttransfusion and sporadic patients. J hepatol 21: 244-249. 6 This article is available from: http://www.imedpub.com/cancer-epidemiology-and-prevention/

16. Sung JL (1984) Hepatitis B virus infection and its sequelae in Taiwan. J Gastroenterol 19: 363-366. Copyright imedpub 7